The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
about
Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal DialysisEqualizer technology followed by DIGE-based proteomics for detection of cellular proteins in artificial peritoneal dialysis effluents.The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation productsUremic Toxicity of Advanced Glycation End Products in CKD.Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients.Hyperbranched polyglycerol is an efficacious and biocompatible novel osmotic agent in a rodent model of peritoneal dialysisGenomic reprograming analysis of the Mesothelial to Mesenchymal Transition identifies biomarkers in peritoneal dialysis patientsAn update on peritoneal dialysis solutions.Pharmacologic targets and peritoneal membrane remodeling.Multidisciplinary clinical strategies for encapsulating peritoneal sclerosis in peritoneal dialysis: update from Japan.Peritoneal dialysis: from bench to bedside."Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?Icodextrin and peritoneal dialysis: advantages and new applications.Peritoneal dialysis: from bench to bedside and bedside to bench.The Natural Time Course of Membrane Alterations During Peritoneal Dialysis Is Partly Altered by Peritonitis.New Insights into the Effects of Chronic Kidney Failure and Dialysate Exposure on the Peritoneum.Peritonitis in the patient on peritoneal dialysis: does the composition of the dialysis fluid make a difference?Dissolved molecular hydrogen (H2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity.Effluent and serum protein N-glycosylation is associated with inflammation and peritoneal membrane transport characteristics in peritoneal dialysis patients.Inflammatory factors for hypoalbuminemia in Japanese peritoneal dialysis patients.Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.Novel peritoneal dialysis solutions--what are the clinical implications?
P2860
Q28390104-5ABD918E-2E26-4383-AB55-5B76D5588817Q35109873-85334C0D-CB76-44BE-B691-6E61965F0614Q36474231-18983BDF-E63E-4A1D-8CB4-ABE8A9D21281Q36514906-C39698D8-A07A-4A82-917A-5F43D82A4C3CQ36566135-BD92E75C-B014-40D0-B82B-34D1C74F0B6BQ36686500-6C766C6A-4346-47AC-8307-C009A39D500FQ37715008-7D8849D5-FFC2-47B3-AFCB-42166CBAC4F7Q37986357-57D73108-9DAC-49D7-A95E-2AC66BF40171Q38187841-78A4DF6D-6DCE-4F3A-B415-2FA0787310C8Q38199756-F8C50B19-28D8-42D9-8D5D-4D61050BDDD6Q38539729-B187F42F-A25A-4423-884B-4A9D88AC3832Q38934145-FE91F3FB-F5DB-491D-A260-FD1571862FFAQ39413030-0599783A-09F9-4E85-851A-77C4C8F1E264Q40743228-CE777DF2-83D9-437A-9173-39D263F1B39AQ40926537-A77F0683-DC5B-4FEB-9631-5A3E476038A1Q42492768-70B94B0D-68A0-4F8F-9356-91B12697963EQ42938782-EF9A48F9-7B51-49BA-BC9E-89B390C9C7AAQ47160299-DEA65ABE-B074-4D92-B770-5A71825F53F7Q48223537-2BABB69C-754B-445B-9B5A-FC3FE6F661DEQ50952596-D1432760-8ED6-487B-8928-B40F2512F024Q51472143-C2A524AE-4AC9-409A-947F-1E1FA0020B6EQ52890076-F2164AFC-423C-48B9-A32C-853FF1CEDEE7
P2860
The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The biocompatibility of neutra ...... it at bench, bedside, or both?
@ast
The biocompatibility of neutra ...... it at bench, bedside, or both?
@en
The biocompatibility of neutra ...... it at bench, bedside, or both?
@nl
type
label
The biocompatibility of neutra ...... it at bench, bedside, or both?
@ast
The biocompatibility of neutra ...... it at bench, bedside, or both?
@en
The biocompatibility of neutra ...... it at bench, bedside, or both?
@nl
prefLabel
The biocompatibility of neutra ...... it at bench, bedside, or both?
@ast
The biocompatibility of neutra ...... it at bench, bedside, or both?
@en
The biocompatibility of neutra ...... it at bench, bedside, or both?
@nl
P2093
P356
P1433
P1476
The biocompatibility of neutra ...... it at bench, bedside, or both?
@en
P2093
Jeffrey Perl
Joanne M Bargman
Sharon J Nessim
P2888
P304
P356
10.1038/KI.2010.515
P407
P577
2011-01-19T00:00:00Z
P6179
1013927426